Rosen & Barkin's 5-Minute Emergency Medicine Consult (85 page)

Read Rosen & Barkin's 5-Minute Emergency Medicine Consult Online

Authors: Jeffrey J. Schaider,Adam Z. Barkin,Roger M. Barkin,Philip Shayne,Richard E. Wolfe,Stephen R. Hayden,Peter Rosen

Tags: #Medical, #Emergency Medicine

BOOK: Rosen & Barkin's 5-Minute Emergency Medicine Consult
3.28Mb size Format: txt, pdf, ePub
ICD9
  • 334.2 Primary cerebellar degeneration
  • 334.3 Other cerebellar ataxia
  • 781.3 Lack of coordination
ICD10
  • G11.1 Early-onset cerebellar ataxia
  • G11.9 Hereditary ataxia, unspecified
  • R27.0 Ataxia, unspecified
ATRIAL FIBRILLATION
Edward Ullman

Terrance T. Lee
BASICS
DESCRIPTION
  • Dysrhythmia characterized by seemingly disorganized atrial depolarizations without effective atrial contraction
  • Caused by multiple re-entrant waveforms within the atria
  • Atrial rate ranges from 350–600 beats per minute (bpm).
  • Results in loss of organized atrial contractions and rapid ventricular rate:
    • Decrease in cardiac output
    • Prone to embolus formation
  • Most common clinical arrhythmia:
    • Prevalence increasing with age
    • Men are at higher risk
ETIOLOGY
  • Systemic disease:
    • HTN
    • Hyperthyroidism
    • Chronic pulmonary disease
    • Infection
    • Pulmonary embolus
    • Hypoxia
    • Drugs (e.g., sympathomimetics)
    • Acute alcohol ingestion (holiday heart syndrome)
    • Obesity
    • Electrolyte disturbance
    • Thyroid disease
  • Underlying cardiac disease:
    • Cardiomyopathy
    • CAD
    • Valvular disease, especially mitral
    • Pericarditis
    • Sick sinus syndrome
    • Myocardial contusion
    • CHF
    • Congenital heart disease
  • Idiopathic:
    • Absence of any known etiologic factor
    • No clinical or echocardiographic evidence of heart disease
DIAGNOSIS
SIGNS AND SYMPTOMS
  • Palpitations
  • Decreased cardiac output:
    • Weakness
    • Light headedness
    • Syncope
    • Hypotension
    • Angina
    • Pulmonary edema
    • Altered mental status
    • Lower extremity edema
    • Hepatojugular reflex
  • Embolus formation:
    • Acute neurologic injury
    • Mesenteric ischemia
History
  • Onset of symptoms
  • Duration
  • Inciting factors
  • Prior episodes of fibrillation
  • Prior heart disease
Physical-Exam
  • Palpitations
  • Irregularly irregular pulse
  • Absence of A
    -
    waves in the jugular venous pulse
  • Pulse deficit with more rapid ventricular rates:
    • The auscultated or palpated apical rate is faster than the rate palpated at the wrist
ESSENTIAL WORKUP
  • History and physical exam:
    • Assess for instability and need for immediate cardioversion
    • Duration of symptoms >48 hr or <48 hr
    • Evidence of systemic disease or underlying cardiac disease
  • ECG: Signs of congestive heart failure
    • Absent P-waves replaced by fibrillatory (f) waves, 350–600 bpm
    • F-waves vary in amplitude, morphology, and intervals
    • R-R intervals are irregularly irregular
    • Absence of an isoelectric baseline
    • Ventricular rate ranges from 80–150 bpm:
      • If rate >200 associated with wide-irregular QRS, consider bypass tract
    • Slower rate suggests abnormal AV node or presence of AV nodal blocking medication
    • Usually narrow QRS complexes unless:
      • Functional aberration
      • Pre-existing bundle branch
      • Pre-excitation with an accessory pathway
DIAGNOSIS TESTS & NTERPRETATION
Lab
  • CBC
  • Electrolytes
  • Cardiac enzymes—if ischemia is a concern
  • Thyroid function
  • Digoxin level—if patient is taking
  • Anticoagulation parameters
  • Urine drug screen
Imaging
  • CXR
  • ECG
DIFFERENTIAL DIAGNOSIS
  • Atrial flutter with variable AV block
  • Multifocal atrial tachycardia
  • Sinus rhythm with frequent premature atrial contractions
  • Atrial tachycardia with variable AV block
TREATMENT
PRE HOSPITAL
  • IV access
  • Monitor
  • Oxygen
  • Cardioversion:
    • In settings where patient is unstable
INITIAL STABILIZATION/THERAPY
  • IV
  • Oxygen
  • Monitor
  • Immediate synchronized electrical cardioversion starting at 200 J if the patient is unstable
ED TREATMENT/PROCEDURES
  • Hemodynamically unstable and life threatening:
    • Myocardial infarction, pulmonary edema, heart failure that does not respond promptly to pharmacological measures
    • Synchronized electrical cardioversion
      • Biphasic: Start at 100 J, higher success rate
      • Monophasic: Start at 200 J
      • Sx duration <48 hr: Consider IV heparin bolus prior.
      • Sx duration >48 hr: IV heparin, transesophageal echo to exclude atrial clot, cardioversion. Anticoagulate for 4 wk. Do not delay echo if life-threatening arrhythmia.
      • Consider pretreatment with antiarrhythmic drugs and use anterior–posterior pad placement to increase likelihood of success
    • Chemical cardioversion:
      • Choice of drug depends on history of CHF, high BP, LV hypertrophy, and CAD
      • Medications may be proarrhythmic and should be used with caution
      • As with electrical cardioversion, appropriate anticoagulation will be necessary depending on the duration and presence/absence of clot
      • Ibutilide
      • Procainamide
      • Flecainide
      • Propafenone
      • Sotalol
  • Hemodynamically stable, mildly symptomatic:
    • Treat underlying cause if 1 is identified.
    • Identify if symptoms are <48 hr. If so consider synchronized cardioversion.
    • >48 hr: Rhythm control does not offer mortality benefit over rate control
    • Use procainamide to treat stable patients with a suspected bypass tract
    • Rate control:
      • Not necessary if rate <100 bpm or if rhythm spontaneously converts to sinus
      • AV nodal blockers (calcium channel blockers, β-blockers, and digoxin) contraindicated if bypass tract suspected such as WPW
      • Calcium channel blockers: Consider in patient with pulmonary disease. Use cautiously in patient with uncompensated CHF and 2nd- or 3rd-degree heart block
      • β-blockers: Consider in patient with coronary artery disease (CAD). Use cautiously in patient with uncompensated CHF, 2nd- or 3rd-degree heart block, and pulmonary disease
      • Digoxin: Consider in patient with pre-existing CHF.
      • Amiodarone: Consider in refractory atrial fibrillation
    • Rhythm control and prophylaxis:
      • Includes procainamide, sotalol, amiodarone, dofetilide
      • Amiodarone: Only agent with strong data to support initiation for outpatient treatment
    • Elective cardioversion:
      • Oral anticoagulation with therapeutic levels for 3 wk prior to and 4 wk after
    • Stable patients with atrial fibrillation and WPW can be treated with procainamide or ibutilide, although cardioversion may be preferred
  • Anticoagulation determined by CHADS2 scoring:
    • 1 point for each of the following:
      • History of cardiac failure
      • History of HTN
      • Age ≥75 yr
      • Diabetes
    • 2 points for a history of stroke or TIA
    • Score of 0:
      • 81–325 mg/day of aspirin
    • Score of 1:
      • Either 81–325 mg/day of aspirin or adjusted-dose warfarin with a target INR of 2.5
    • Score >1:
      • Adjusted-dose warfarin with a target INR of 2.5 (range 2–3)
    • Adjusted annual stroke rate increases from 1.9% for a CHADS2 score of 0 to 18.2% for a CHADS2 score of 6
    • Aspirin:
      • Patients with contraindications to anticoagulation and unreliable individuals
      • Patients with low stroke risk
MEDICATION
  • Metoprolol:
    • 5–10 mg slow IV push at 5 min intervals to total of 15 mg
    • 25 mg–100 mg oral BID
  • Diltiazem:
    • 0.25 mg/kg IV over 2 min; if unsuccessful, repeat in 15 min as 0.35 mg/kg IV over 2 min; maintenance infusion of 5 mg/h usually started to maintain rate control.
    • 120–300 mg oral daily
  • Digoxin:
    • 0.5 mg IV initially, then 0.25 mg IV q4h until desired effect
  • Esmolol:
    • 0.5 mg/kg over 1 min; maintenance infusion at 0.05 mg/kg/min over 4 min
  • Propranolol:
    • 0.1 mg/kg IV divided into equal doses at 2–3 min intervals
  • Verapamil:
    • 2.5–5 mg IV bolus over 2 min; may repeat with 5–10 mg q15–30min to max. of 20 mg
    • 120–300 mg PO daily
  • Amiodarone:
    • 5–7 mg/kg over 30–60 min, then 1.2–1.8 g/d continuous infusion or in divided PO doses until 10 g total
    • 600–800 mg/d divided dose until 10 g total, then 200–400 mg/d maintenance
  • Procainamide: 15–18 mg/kg loading dose administered as a slow infusion over 30 min. Max.: 1 g. Then 2–6 mg/min infusion.
  • Quinidine gluconate: 324–648 mg PO q8–12h: (extended release tabs)
  • Ibutilide: 1 mg IV for patients >60 kg; 0.01 mg/kg IV for patients <60 kg infused over 10 min; can be repeated once if sinus rhythm not restored within 10 min. Requires normal QTc, no history of torsades, no hypokalemia. Patients must be monitored for 4 h for QT prolongation, Torsades de Pointes, and ventricular tachycardia.
  • Flecainide: 2 mg/kg IV at 10 mg/min PO. Do not give in patients with structural heart disease.
  • Propafenone: 1–2 mg/kg IV at 10 mg/min
  • Sotalol: 75 mg infused IV over 5 h BID if CrCl >60 mL/min. Give QD if CrCl 40–60 mL/min
  • Heparin: Load 80 U/kg IV; infusion at 18 U/kg/h. Dosage adjustment required in obese patients
  • Low-molecular-weight heparin: 1 mg/kg SQ BID
  • Warfarin sodium: 2.5–5 mg/d PO, dosage adjustments based on INR
  • Aspirin: 50–325 mg/d

Other books

Thefts of Nick Velvet by Edward D. Hoch
The Triad of Finity by Kevin Emerson
The Shangani Patrol by Wilcox, John
Mission Unstoppable by Dan Gutman
Trophy by Julian Jay Savarin
The Poison Sky by John Shannon
Lick: Stage Dive 1 by Scott, Kylie
The Dragon's Banner by Jay Allan
The Viper's Fangs (Book 2) by Robert P. Hansen